Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer

International Journal of Clinical Oncology

Volumn 10, Issue 5, 2005, Pages 333-337

  Segawa, Takehiko ^a   Kamoto, Toshiyuki ^a   Kinoshita, Hidefumi ^a   Kunishima, Yasuharu ^a   Yoshimura, Koji ^a   Ito, Akihiro ^a   Takahashi, Takeshi ^a   Higashi, Shin ^a   Nakamura, Eijiro ^a   Nishiyama, Hirofumi ^a   Ito, Noriyuki ^a   Yamamoto, Shingo ^a   Habuchi, Tomonori ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Carboplatin; Chemotherapy; Estramustine; Paclitaxel; Prostate cancer

Indexed keywords

CARBOPLATIN; ESTRAMUSTINE PHOSPHATE; PACLITAXEL;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; HUMAN; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 27144531754     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-005-0513-x     Document Type: Article

References (19)

1. A Jemal T Murray A Samuels 2003 Cancer statistics, 2003 CA Cancer J Clin 53 5 26
2. AF Baker RT Dorr 2001 Drug interactions with the taxanes: clinical implications Cancer Treat Rev 27 221 233
3. U Vaishampayan RE Parchment BR Jasti 1999 Taxanes: an overview of the pharmacokinetics and pharmacodynamics Urology 54 22 29
4. MH Kang WD Figg W Dahut 1999 Taxanes in hormone-refractory prostate cancer Cancer Pract 7 270 272
5. BJ Roth BY Yeap G Wilding 1993 Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group Cancer 72 2457 2460
6. MA Bookman BE Greer RF Ozols 2003 Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5 Int J Gynecol Cancer 13 735 740
7. G Fountzilas HP Kalofonos U Dafni 2004 Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 10 1517 1526
8. JH Schiller D Harrington CP Belani 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98
9. K Kelly J Crowley PA Bunn Jr 2001 Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 3210 3218
10. G Hudes 1997 Estramustine-based chemotherapy Semin Urol Oncol 15 13 19
11. WK Kelly T Curley S Slovin 2001 Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer J Clin Oncol 19 44 53
12. DB Solit M Morris S Slovin 2003 Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma Cancer 98 1842 1848
13. WK Kelly AX Zhu H Scher 2003 Dose escalation study of intravenous estramustine phosphate in combination with paclitaxel and carboplatin in patients with advanced prostate cancer Clin Cancer Res 9 2098 2107
14. S Urakami M Igawa N Kikuno 2002 Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer J Urol 168 2444 2450
15. RB Weiss RC Donehower PH Wiernik 1990 Hypersensitivity reactions from taxol J Clin Oncol 8 1263 1268
16. GJ Bubley M Carducci W Dahut 1999 Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 11 3461 3467
17. HP Schmid R Morant J Bernhard 2003 Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma Eur Urol 43 28 30
18. LJ van Warmerdam MT Huizing G Giaccone 1997 Clinical pharmacology of carboplatin administered in combination with paclitaxel Semin Oncol 24 S2 104
19. IF Tannock R de Wit WR Berry 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512